Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Imatinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 known ✓ | P00519 | 20/20 | 0.98 |
| ▸ | BCR known ✓ | P11274 | 14/20 | 0.98 |
| ▸ | KIT known ✓ | P10721 | 12/20 | 0.98 |
| ▸ | PDGFRB known ✓ | P09619 | 2/20 | 0.98 |
| ▸ | ABL2 | P42684 | 7/20 | 0.98 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.98 |
| ▸ | LYN | P07948 | 3/20 | 0.98 |
| ▸ | SRC | P12931 | 2/20 | 0.98 |
| ▸ | SYK | P43405 | 2/20 | 0.98 |
| ▸ | PLK4 | O00444 | 1/20 | 0.98 |
| ▸ | DDX3X | O00571 | 1/20 | 0.98 |
| ▸ | GAK | O14976 | 1/20 | 0.98 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.98 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.98 |
| ▸ | CA12 | O43570 | 1/20 | 0.98 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.98 |
| ▸ | EGFR | P00533 | 1/20 | 0.98 |
| ▸ | CA1 | P00915 | 1/20 | 0.98 |
| ▸ | CA2 | P00918 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Imatinib SCHEMBL2236091 | 0.99 | ABL1 (1.00) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL29355523 | 0.99 | ABL1 (1.00) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL29351601 | 0.99 | ABL1 (1.00) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL3827 | 0.99 | ABL1 (1.00) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL15201213 | 0.98 | ABL1 (0.98) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL2929858 | 0.98 | ABL1 (0.98) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL1977949 | 0.98 | ABL1 (0.98) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL3138052 | 0.98 | ABL1 (0.98) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL1462774 | 0.98 | ABL1 (0.98) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL529425 | 0.98 | ABL1 (0.98) | ABL1BCRKITABL2PDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108164505-B | Synthesis method of imatinib | 扬州大学 | 2020-11-03 | — | — | CN | claimed |
| US-11980689-B2 | Inhaled imatinib for treatment of pulmonary arterial hypertension (PAH) | AVALYN PHARMA INC. (US) | 2024-05-14 | — | — | US | disclosed |
| US-20220087937-A1 | AEROSOL TYROSINE KINASE INHIBITOR COMPOUNDS AND USES THEREOF | AVALYN PHARMA INC. | 2022-03-24 | — | — | US | disclosed |
| US-20210093570-A1 | INHALED IMATINIB FOR TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) | AVALYN PHARMA INC. | 2021-04-01 | — | — | US | disclosed |
| US-20210093569-A1 | INHALED IMATINIB FOR TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) | AVALYN PHARMA INC. | 2021-04-01 | — | — | US | disclosed |
| EP-3782604-A1 | AEROSOL TYROSINE KINASE INHIBITOR COMPOUNDS AND USES THEREOF | Windward Pharma, Inc. (US) | 2021-02-24 | — | — | EP | disclosed |
| CN-108164505-B | Synthesis method of imatinib | 扬州大学 | 2020-11-03 | — | — | CN | disclosed |
| EP-3027026-A1 | AEROSOL TYROSINE KINASE INHIBITOR COMPOUNDS AND USES THEREOF | Windward Pharma, Inc. (US) | 2016-06-08 | — | — | EP | disclosed |
| US-20150044288-A1 | AEROSOL TYROSINE KINASE INHIBITOR COMPOUNDS AND USES THEREOF | AVALYN PHARMA INC. | 2015-02-12 | — | — | US | disclosed |
| WO-2015017728-A1 | AEROSOL TYROSINE KINASE INHIBITOR COMPOUNDS AND USES THEREOF | WINDWARD PHARMA, INC. (US) | 2015-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210093569-A1 | INHALED IMATINIB FOR TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) | ALK, JAK1, PAH | ABL1 4/4885BCR 353/4885KIT 204/4885 |
| US-20150044288-A1 | AEROSOL TYROSINE KINASE INHIBITOR COMPOUNDS AND USES THEREOF | ALK, JAK1, ABL1 | ABL1 3/4885BCR 280/4885KIT 379/4885 |
| US-20210093570-A1 | INHALED IMATINIB FOR TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) | ALK, JAK1, PAH | ABL1 4/4885BCR 353/4885KIT 204/4885 |
| US-20220087937-A1 | AEROSOL TYROSINE KINASE INHIBITOR COMPOUNDS AND USES THEREOF | ALK, JAK1, ABL1 | ABL1 3/4885BCR 280/4885KIT 379/4885 |
| US-11980689-B2 | Inhaled imatinib for treatment of pulmonary arterial hypertension (PAH) | ALK, JAK1, PAH | ABL1 4/4885BCR 353/4885KIT 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.